secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-116219
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics appoints new Principal Financial Officer and Principal Accounting Officer
--------------------------------------------------------------------------------

- Melissa Orilall, VP Global Financial Operations at Agenus, appointed Principal Financial Officer effective March 13, 2026.
- Austin Charette, Senior Director Financial Reporting & Compliance at Agenus, appointed Principal Accounting Officer effective same date.
- Both provide services via Amended Intercompany Services Agreement with Agenus; no direct compensation from MiNK.
- No new arrangements or modifications tied to these designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526116219/0001193125-26-116219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526116219/inkt-20260313.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-116219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer